| 唐慧敏,黄灵炎,王明山,等.Ⅱ型糖尿病对乳腺癌预后的影响分析[J].肿瘤学杂志,2024,30(11):924-931. |
| Ⅱ型糖尿病对乳腺癌预后的影响分析 |
| Effect of Type 2 Diabetes Mellitus on Prognosis of Breast Cancer |
| 投稿时间：2024-04-14 |
| DOI：10.11735/j.issn.1671-170X.2024.11.B006 |
|
 |
| 中文关键词: 乳腺癌 2型糖尿病 乳腺癌特异性生存 生存 |
| 英文关键词:breast cancer type 2 diabetes mellitus breast cancer-specific survival overall survival |
| 基金项目:厦门大学附属翔安医院青年科研基金项目（XM01040005） |
|
| 摘要点击次数: 58 |
| 全文下载次数: 8 |
| 中文摘要: |
| 摘 要：［目的］ 分析2型糖尿病（type 2 diabetes mellitus，T2DM）对乳腺癌患者死亡风险的影响。［方法］ 通过中英文数据库检索，分析并提取乳腺癌合并T2DM相关生存曲线数据，通过Meta分析探究T2DM对乳腺癌预后的影响。研究纳入2010年1月至2016年12月大连医科大学附属第一医院收治的981例乳腺癌患者的临床病理资料，其中无T2DM 768例，合并T2DM 213例。随访截止日期2022年6月，采用单因素和多因素Cox回归模型分析T2DM、乳腺癌临床特征与乳腺癌特异性生存（breast cancer-specific survival，BCSS）和乳腺癌总生存（overall survival，OS）的相关性。［结果］ Meta分析发现，在乳腺癌BCSS及OS 分析中，糖尿病与乳腺癌的不良预后相关，总风险比分别为1.15（95%CI：1.05~1.26）和1.87（95%CI：1.47~2.37）。981例乳腺癌患者中，无T2DM组患者1、3、5年生存率分别为99.86%、99.86%、84.76%；而合并T2DM组患者1、3、5年生存率分别为99.48%、98.44%、83.13%。多因素分析发现年龄、T2DM是乳腺癌BCSS和OS的独立预后因素。合并T2DM组患者发生乳腺癌特异性死亡风险是无T2DM组的2.173倍（HR=2.173，95%CI：1.244～3.860，P=0.008）；合并T2DM组患者发生全因死亡风险是无T2DM组的1.990倍（HR=1.990，95%CI：1.133～3.495，P=0.017）。［结论］ 合并T2DM的乳腺癌患者预后较差，应在制定诊疗计划时给予更多关注。 |
| 英文摘要: |
| Abstract： ［Objective］ To analysis the impact of type 2 diabetes mellitus (T2DM) on the mortality risk of breast cancer patients. ［Methods］ A meta analysis was conducted to analyze the effect of T2DM on the prognosis of breast cancer. The clinical study enrolled 981 breast cancer patients admitted to the First Affiliated Hospital of Dalian Medical University from January 2010 to December 2016， including 768 cases without T2DM and 213 cases with T2DM. Patients were followed up till June 2022. Univariate and multivariate Cox regression models were used to analyze the correlation of T2DM and clinical pathological features with breast cancer-specific survival (BCSS) and overall survival(OS) of patients. ［Results］ Meta analysis founded that diabetes was associated with poor prognosis of breast cancer， and the total risk for BCSS and OS was 1.15(95%CI：1.05~1.26) and 1.87 (95%CI：1.47~2.37)， respectively. Clinical study showed that the 1-， 3- and 5-year survival rates of patients without T2DM were 99.86%， 99.86% and 84.76% respectively， the survival rates of patients with combined T2DM were 99.48%， 98.44% and 83.13%， respectively. Multivariate Cox regression revealed that age and T2DM were independent prognostic factors of BCSS and OS. The breast cancer-specific mortality risk for patients with T2DM was significantly higher than that without T2DM (HR=2.173， 95% CI：1.244～3.860， P=0.008)， the all-cause mortality risk in patients with T2DM group was also higher than that without T2DM(HR=1.990， 95%CI： 1.133～3.495， P=0.017). ［Conclusion］ Breast cancer patients with T2DM have a poorer prognosis than those without T2DM. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |